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Pulmonary arterial hypertension (PAH) is a rare multifactorial disease with an unfavorable prognosis.
Sildenaﬁl therapy can improve functional capacity and pulmonary hemodynamics in PAH patients.
Nowadays, it is increasingly recognized that the effects of sildenaﬁl are pleiotropic and may also involve
changes of the pro-/antioxidant balance, lipid peroxidation and autonomic control. In present study we
aimed to assess the effects of sildenaﬁl on the fatty acids (FAs) status, level of hydroxynonenal (HNE) and
heart rate variability (HRV) in PAH patients. Patients with PAH were characterized by an increase in HNE
and changes in the FAs composition with elevation of linoleic, oleic, docosahexanoic acids in phospho-
lipids as well as reduced HRV with sympathetic predominance. Sildenaﬁl therapy improved exercise
capacity and pulmonary hemodynamics and reduced NT-proBNP level in PAH. Antioxidant and anti-
inﬂammatory effects of sildenaﬁl were noted from the signiﬁcant lowering of HNE level and reduction of
the phopholipid derived oleic, linoleic, docosahexanoic, docosapentanoic FAs. That was also associated
with some improvement of HRV on account of the activation of the neurohumoral regulatory component.
Incomplete recovery of the functional metabolic disorders in PAH patients may be assumed from the
persistent increase in free FAs, reduced HRV with the sympathetic predominance in the spectral struc-
ture after treatment comparing to control group. The possibilities to improve PAH treatment efﬁcacy
through mild stimulation of free radical reactions and formation of hormetic reaction in the context of
improved NO signaling are discussed.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article u
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Pulmonary arterial hypertension (PAH) is a rare, progressive dis-
ease characterized by sustained pulmonary arterial vasoconstriction
and vascular remodeling ultimately leading to right ventricular failure
and death. The pathophysiology of PAH in complex and involves ab-
normal proliferation of the vascular smooth muscle and endothelial
cells, inﬁltration by the inﬂammatory cells, and ﬁbrosis of the vascular
elements [20]. Multiple factors including endothelial dysfunction with
reduced NO bioavailability, increased production of reactive oxygen
species (ROS), impaired synthesis of prostaglandin with PGI2 deﬁ-
ciency and excessive production of various mediators (angiotensin II,
endotelin-1, etc.) play role in the pathologic remodeling of the pul-
monary vasculature [1]. Recently, the action of the inﬂammatory,
procoagulant, antiapoptotic, and autoimmune mediators, as well as
cell–cell and cell–matrix interactions have been recognized asnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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gress in understanding PAH and major advances in its treatment the
prognosis of the disease still remains unfavorable with the mortality
rate of 10–15% per year and median survival of approximately 7 years
[5] underscoring the need for more effective therapeutic options.
Currently approved PAH speciﬁc therapies include prostacy-
clins, phosphodiesterase inhibitors, endothelin receptor antago-
nists, and soluble guanylyl cyclase agonists [21]. Impaired synth-
esis of prostacyclin from arachidonic acid was the ﬁrst pathobio-
logical mechanism described in PAH, which pioneered effective
drug development [12]. Reduced expression of prostacyclin syn-
thase (PGIS) was found in pulmonary arteries in PAH patients [67],
and peroxynitrite-mediated nitration of speciﬁc protein tyrosine
residues was shown to be responsible for selective inactivation of
PGIS and development of endothelial dysfunction [82,14].
Increased production of ROS and oxidative stress (OS) are the
major contributors to the disorders in the L-arginine-NO-signaling
pathway with changes in NO synthase (NOS) activity and NO de-
ﬁciency and impaired pulmonary vasodilatory responses being
characteristic features of PAH [23]. The underlying mechanisms of
the derangements in NO synthesis are related either to the oxi-
dative loss of NOS cofactor tetrahydrobiopterin (BH4) or oxidative
attack on the zinc tetrathiolate cluster, which is an important
mediator for the NOS dimeric structure [1]. Moreover, increased
nonenzymatic NO production in hypoxic and oxidative environ-
ment rather promotes formation of peroxinitrite than improves
NO bioavailability.
OS is commonly recognized player at the ﬁeld of PAH. Signs of
OS with excessive lipid peroxidation were demonstrated in PAH
patients by increased levels of isoprostanes in urine [13] and
malondialdehyde in plasma [32]. The other product of lipid per-
oxidation is hydroxynonenal (HNE). It is regarded not only as a
useful marker of oxidative inﬂammatory condition but also exerts
a wide range of pathophysiological effects, including synthesis and
release of vasoactive mediators, breakdown of the endothelial
barrier function and induction of the pro-inﬂammatory phenotype
within the vessel wall making the study of HNE role in PAH par-
ticularly important [7]. The opposing effects of HNE on the NO
homeostasis have been described [56], although the data on its
role in PAH is missing.
Changes in the fatty acid (FA) composition were shown to in-
terfere with NO signaling. NO production can be stimulated by the
polyunsaturated FA (PUFA) such as arachidonic, eicosapentanoic
(EPA), and docosahexanoic (DHA) acids [43,3,39]. This relationship
is bidirectional as inhibition of NO synthesis was demonstrated to
increase erythrocyte membrane ﬂuidity due to the higher content
of the unsaturated FAs [16], while administration of L-arginine
increased levels of linoleic (LA), γ-linolenic acid (GLA) and diho-
mo-GLA [45]. Increased levels of free FAs in blood have been clo-
sely linked to endothelial dysfunction and altered eNOS activity
attributed to the impaired action of the phospholipase C activating
receptor agonists (such as acetylcholine, ATP, bradykinin) and re-
duced [Ca2þ]i increments [17,64]. Thus, metabolic alterations
contributing to the impaired NO bioavailability observed in PAH
involve alterations in the FAs status and potentiation of the L-ar-
ginine-NO-system during treatment may be accompanied by
changes in the lipid composition.
At present, targeting L-arginine-NO pathway is a cornerstone
strategy in PAH treatment. The approved therapeutic options in-
clude sildenaﬁl, tadalaﬁl, and vardenaﬁl – inhibitors of phospho-
diesterase type 5 (PDE-5), and riociguat, which stimulates soluble
guanylyl cyclase and promotes cGMP synthesis [55,21]. Sildenaﬁl
has the highest level of evidence in PAH [21]. As the other PDE-5
inhibitors it blocks enzymatic degradation of the second messen-
ger cGMP to GMP, increases intracellular cGMP level and leads to
activation of the protein kinase G (PKG) with subsequentrelaxation of smooth muscle cells, reduction of vascular re-
modeling and vasoconstriction. At the same time, precise mole-
cular mechanisms of the protective effects of sildenaﬁl are not
completely understood. Recently, it was demonstrated that silde-
naﬁl suppressed multiple cytokines involved in neutrophil and
mononuclear cell recruitment and reduced NF-kB and p38 MAPK
activation in lungs from rats with monocrotaline induced PAH
[36]. Moreover, its use caused stimulation of another PDE type
3-PKA pathway and targeted mitochondrial KþATP channels, mi-
tochondria and inﬂammation in hypertrophied right ventricle in
PAH patients [48]. The inhibitory action of sildenaﬁl on the main
sources of free radicals production such as xanthine oxidase [63]
and NADPH oxidase [47] points to its role as an antioxidant. Thus,
the action of sildenaﬁl is not limited to mechanistic inhibition of
PDE5-PKG system but also includes modulation of the in-
ﬂammatory and redox status, which are increasingly recognized as
important contributors to PAH progression.
Development of PAH is characterized not only by the defective
vasodilator but also exaggerated vasoconstrictor responses. The
latter involve activation of the sympathetic nervous system, which
was conﬁrmed by the studies of the heart rate variability (HRV) in
PAH subjects [6,71]. Interestingly, that inhibition of NOS in healthy
volunteers caused sympathetic activation [76], while administra-
tion of PDE-5 inhibitor improved NO bioavailability and prevented
hypoxic pulmonary hypertension [42]. There is increasing evi-
dence that HRV is informative not only about the autonomic bal-
ance but also reﬂects the severity of the inﬂammatory conditions
and depth of the oxidative stress [74] which has not been ad-
dressed in PAH.
In present study we aimed to assess the effects of sildenaﬁl on
the FAs status, level of hydroxynonenal (HNE) and heart rate
variability (HRV) in PAH patients. We hypothesize that improve-
ment of NO bioavailability with sildenaﬁl will reduce lipid per-
oxidation, diminish signs of OS, providing antioxidant effect in
PAH patients. Correction of the metabolic disorders at the level of
an organism can be reﬂected by increased HRV and improvement
in the balance between autonomic components which inﬂuence
the heart rhythm.2. Materials and methods
2.1. Selection of patients and study design
Patients with newly diagnosed PAH (idiopathic, familial or oc-
curring after surgical repair of congenital systemic-to-pulmonary
shunts that had been performed at least ﬁve years previously)
with a six-minute walking distance from 100 m to 450 m were
included into the study. PAH was characterized by the presence of
pre-capillary PH, i.e., mPAPZ25 mmHg, pulmonary artery wedge
pressure r15 mmHg by right heart catheterization, in the absence
of other causes of pre-capillary PH. Thermodilution method was
used for cardiac output measurement. Upon conﬁrmation of PAH
sildenaﬁl at a dose of 25 mg three times per day was initiated in
addition to the conventional therapies including diuretics and
anticoagulants. The duration of the study period was 12 weeks.
Patients treated with other PAH speciﬁc medications such as in-
haled or intravenous prostanoids, endothelin receptor blocker,
calcium channel blockers and supplementation with L-arginine,
and ﬁsh oil were not included into the study. Patients remained on
their usual diet throughout the study. Healthy volunteers com-
prised a control group. They underwent standard clinical evalua-
tion, blood sampling and HRV measurement once and did not
receive any medications. The study was approved by Ethics Com-
mittee of the Danylo Halytsky Lviv National Medical University
and written informed consent was obtained from all participants.
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The measures of efﬁcacy included the change in exercise ca-
pacity, as measured by the total distance walked in six minutes
(6 min walk test, 6MWT), from baseline to week 12, score on the
Borg scale of dyspnea (with 0 representing no dyspnea and 10
maximal dyspnea), World Health Organization (WHO) functional
class (FC) of PAH. Other measures of efﬁcacy were the changes in
the peak pressure gradient of tricuspid regurgitation and right
ventricle diameter by echocardiography [20]. Physical examina-
tions and laboratory tests were performed before and 12 weeks
after initiation of sildenaﬁl therapy. Fasting blood samples were
obtained by venepuncture of the cubital vein, centrifuged and
serum was stored under 80 °C until the analysis.
2.3. Fatty acids determination
Phospholipid and free FAs were determined by gas chromato-
graphy according to the method of Christie [11]. Lipid components
were isolated by Folch extraction using chloroform/methanol mixture
(2:1, v/v) in the presence of 0.01% butylated hydroxytoluene (BHT).
Using TLC, free fatty acids and total phospholipids were separated with
the mobile phase heptane–diisopropyl ether–acetic acid (60:40:3, v/v/
v). All lipid fractions were transmetylated to fatty acid methyl esters
(FAMEs) with boron triﬂuoride in methanol reagent under nitrogen
atmosphere without previous separation from the layer. The FAMEs
were analyzed by gas chromatography with a ﬂame ionization de-
tector (FID) on Clarus 500 Gas Chromatograph (Perkin Elmer). Se-
paration of FAMEs was carried out on capillary column coated with
Varian CP-Sil88 stationary phase. Operating conditions were as fol-
lows: the split–splitless injector was used in split mode with a split
ratio of 1:20. The injection volume of the sample was 2 mL. The injector
and FID detector temperatures were kept at 260 °C. The column
temperature was programmed from 150 °C (2 min) to 230 °C (10 min)
at 4 °C/min. The carrier gas was helium at a ﬂow rate of 1 mL/min. 1,2-
dinonadecanoyl-sn-glycero-3-phosphocholine (19:0 PC) was used as
an internal standard. The LOD for FAMEs standards was in the range of
150–250 ng/ml and the LOQ was in the range of 500–700 ng/mL, at a
signal-to-noise ratio of 3 and 10, respectively. The precision of LOQ
was 7.5% (CV). The linear dynamic range was 500–50000 ng/ml.
2.4. Lipid peroxidation products and NT-proBNP determination
4-hydroxynonenal (4-HNE) was assayed as a ﬂuorimetric de-
rivative with 1,3-cyclohexandione (CHD) [75]. Samples were
mixed with methanol (1:1, V/V) and centrifuged at 850g for
10 min. CHD reagent was added to supernatant and obtained
mixture was incubated for 1 h at 60 °C. The samples were puriﬁed
by using Sep-pak ODS columns (Waters Associates, USA) and
eluted with methanol. The eluent was evaporated to dryness un-
der nitrogen and samples were reconstituted in 150 μl of metha-
nol and subjected to HPLC. Chromatographic separation of CHD-
adducts was carried out on RP C18 column with a linear gradient
mobile phase consisted of methanol (MeOH), water and tetra-
hydrofuran [75]. The HPLC ﬂuorescence detector was used with
excitation at 380 nm and emission at 445 nm. The retention time
was 20.07 min. The concentration of 4-HNE in the samples was
calculated using a calibration curve (625–2000 nmol/l, R2
¼0.9997).
Evaluation of the N-terminal natriuretic peptide (NT-proBNP)
level in the venous blood was performed by electro-chemilumi-
nesence immunoassay using Roche Diagnostic reagents. The re-
ference values of NT-proBNP for the individual aged 18–44 years
areo85.8 pg/ml for male ando130 pg/ml for female.2.5. Study of heart rate variability
During quiet wakefulness in the morning hours the short time
ECG records were obtained using computer electrocardiograph
“VNS-Micro” (Neurosofts, Russia). After 20 min of rest, subjects
were asked to stay supine quietly for 5 min for stationary HRV
recording; afterwards they were asked to stand up rapidly and
remained in the standing position for 6 min (orthostatic test). RR
intervals were determined with a sampling frequency of 2 kHz and
were analyzed with “Poly-Spectrum” (Neurosofts, Russia) soft-
ware designed according to HRV standards [28]. The time-domain
indices – standard deviation of normal RR intervals (SDNN), the
square root of the mean squared differences of successive RR in-
terval (RMSSD), and percentage of differences between adjacent
normal RR intervals exceeding 50 milliseconds (pNN50) were
determined. The power spectral analysis was performed sequen-
tially with a fast Fourier transformation. The following frequency-
domain variables were studied: total power (TP, 0.01 to 0.40 Hz),
high frequency power (HF, 0.15 to 0.40 Hz), low frequency power
(LF, 0.04 to 0.15 Hz), and very low frequency power (VLF, 0.01 to
0.04 Hz).
2.6. Statistical analysis
Data was processed using Microsoft Excel for storage and basic
calculations. Statistical calculations were performed by GraphPad
Prism (version 5.00, open source). Normal distribution of the ob-
tained data was conﬁrmed with Shapiro–Wilk's W-test. Data are
presented as means7standard deviation (M7SD), median
(quartile range), means7standard error mean (M7SEM). The
unpaired and paired t-test for independent variables was utilized
to compare means between groups. The change in Borg dyspnea
score was assessed by nonparametric Wilcoxon’s matched pairs
test. Values of Po0.05 were considered signiﬁcant.3. Results
3.1. Baseline characteristics of PAH patient population
From July 2009 to June 2012 totally seven newly diagnosed
treatment naive patients with PAH and seven healthy controls
were enrolled. Demographic data of the patients and healthy
controls is presented in Table 1. Among the PAH patients four were
with familial PAH, and two with idiopathic PAH and one patient
with PAH related to repaired congenital systemic-to-pulmonary
shunt. Groups of patients and control were compatible by age and
gender. Most subjects in PAH group were WHO functional class II
(85.7%). One patient from PAH group had mild arterial hyperten-
sion. The mean 6MWD was 361.1 m in PAH group. Main para-
meters of pulmonary hemodynamics are presented in Table 1. The
values of NT-proBNP in PAH patients were signiﬁcantly increased
over the reference range.
3.2. Comparison between PAH patients and control
Groups of PAH patients and control were compatible by age,
gender and BMI. PAH subjects had an increased heart rate but no
signiﬁcant difference in blood pressure comparing to healthy vo-
lunteers was noted (Table 1). Higher levels of unsaturated FA (oleic
(18:1), linoleic (18:2)) in free and phospholipid derived fractions
were observed in PAH patients (Table 2). The total amount and
majority of the saturated FA within phospholipids were elevated in
PAH comparing to control group. Interestingly, that insigniﬁcant
increase of DHA (22:6) in phospholipids was observed before
treatment in PAH. The ω6/ω3 ratio as well as level of the oxidative
Table 1
Characteristics of patients with PAH and healthy controls.
Variable PAH patient, n¼7 Control, n¼7 p Value
Age,years 30.977.3 30.674.2 0.930
Gender, M/F 3/4 3/4 1.000
FC, II/III 6/1 - -
BMI, kg/m2 26.376.7 24.873.4 0.611
Heart rate, bpm 84.678.6 69.376.2 0.012
Syst. BP, mmHg 120.8710.7 117.877.6 0.590
Diast. BP, mmHg 82.8711.7 79.177.4 0.530
Hypertension, n (%) 1 (14.3) - -
6-MWT, m 361.1769.4 4 580 male* -
4 500 female*
NT-proBNP, pg/ml 310171952 o 85.8 male* -
o 130 female*
mPAP, mmHg 58.9716.3 7-19* -
PAWP, mmHg 9.573.1 5-13*
PVR, dyn sec m2/cm5 10527494 11-99* -
CO, L/min 3.46 (3.22, 4.16) 4.4–8.4* -
CI, L/min/m2 2.00 (1.88, 2.27) 2.6–4.2* -
FEV1, % 79.076.5 - -
VC, % 76.077.5 - -
Data are presented as mean7SD or median (interquartile range).
* Values were taken from [50]; PAH¼pulmonary arterial hypertension; M/
F¼male/female; FC¼ functional class; BMI¼body mass index; 6MWT¼6-min walk
test; NT-proBNP¼N-terminal pro-brain natriuretic peptide; mPAP¼mean pulmon-
ary arterial pressure; PAWP – pulmonary artery wedge pressure; PVR¼pulmonary
vascular resistance; CO¼cardiac output; CI¼cardiac index; FEV1 – forced expira-
tory volume in 1 s; VC- vital capacity.
Table 2
Changes in the fatty acids composition associated with sildenaﬁl therapy in PAH
Fatty acids PAH Control
Before
treatment
After
treatment
Free FA
Saturated
Palmitic acid, (16:0) 1.4070.26 1.6470.18# 1.0870.08
Stearic acid, (18:0) 0.8570.13 1.2270.08# 0.9870.09
Sum 2.2470.16 2.8570.25# 2.0570.17
Unsaturated
Palmitoleic acid, (16:1, cis-
9)
0.1170.05 0.1370.02# 0.0570.01
Oleic acid, (18:1, cis-9) 0.5170.07 1.1370.28# 0.4370.06
Linoleic acid, (18:2, cis-
9,12)
0.8370.31 1.1470.24# 0.3670.14
Sum 1.4570.33 2.4070.52# 0.8370.20
Phospholipids
Saturated
Palmitic acid, (16:0) 46.3071.68# 44.7172.13 42.1872.06
Stearic acid, (18:0) 16.7370.98# 15.3871.43 13.0471.73
Arachidic acid, (20:0) 0.1870.01# 0.1870.02# 0.1270.02
Behenic acid, (22:0) 0.1970.04 0.2570.05a 0.1270.08
Sum 63.4072.70# 60.5373.60 55.4773.41
Unsaturated
Palmitoleic acid, (16:1, cis-
9)
1.5770.07 1.4770.06 1.4170.08
Oleic acid, (18:1, cis-9) 12.0671.15# 10.6270.64 9.3870.55
Linoleic acid, (18:2, cis-
9,12)
26.0271.78# 22.8872.81 21.3173.06
Arachidonic acid, (20:4, cis-
5,8,11,14,17)
20.9371.48 19.1871.25 19.3372.46
Eicosapentanoic acid,
(20:5, cis-5,8,11,14,17) 1.5870.08 1.5370.10 1.7670.22
Nervonic acid, (24:1, cis-15) 0.5570.04# 0.6070.06# 0.3970.04
Docosapentanoic acid,
(22:5, cis- 7,10,13,16,19) 0.9270.12 0.8270.11 0.8170.18
Docosahexanoic acid,
(22:6, cis- 4,7,10,13,16,19) 3.9070.17 3.3370.34* 3.3270.86
Sum 67.5274.0 60.4273.60 57.7176.15
Note: Data are presented as mean7SEM in ng/mL;
# difference signiﬁcant between PAH before or after treatment and control
group, po0.05.
* difference signiﬁcant before and after sildenaﬁl, po0.05;
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were signiﬁcantly elevated in PAH (Fig. 1).
Study of HRV showed marked reduction of the time-domain
indexes in supine position in PAH population. SDNN and RMSSD
were reduced to 18.3710.1 ms and 12.7711.2 ms respectively
(Table 3). Prominent lowering in total spectral power (TP
5247469 ms2 vs. 21917975 ms2 in control group) was accom-
panied by marked reduction in the VLF, LF, and HF in PAH patients
(Fig. 2). Sympathetic predominance with higher LF/HF ratio
(3.772.2 vs. 2.774.2) in supine position and similar tendency in
orthostasis were noted.
3.3. Changes in clinical variables and hemodynamics with sildenaﬁl
therapy
Twelve weeks of sildenaﬁl therapy administered to newly di-
agnosed PAH patients caused increase in 6MWD from
361.1769.4 m to 388.7760.2 m (Fig. 3). At the same time, no
major changes in the Borg dyspnea index were noted (4.8671.68
before vs. 4.7171.70 after treatment, p¼0.773). Most of the pa-
tients remained within the same FC II (n¼6, 85.7%), and one pa-
tient initially in FC III improved to FC II. Some decrease in the peak
velocity of the tricuspid regurgitation, the parameter which cor-
relates with the systolic pressure in the pulmonary artery from
66.9725.3 mmHg to 61.6725.9 mmHg without major changes in
the diameter of the right ventricle were noted during echo-
cardiographic study (Fig. 3). In general, sildenaﬁl was well toler-
ated with one out of seven patients reporting headache of mild
intensity during treatment.
3.4. Changes in FAs composition and HNE with sildenaﬁl therapy
Initially slightly elevated levels of free saturated and un-
saturated FAs in PAH were further increasing reaching statistical
signiﬁcance with sildenaﬁl therapy comparing to control (Table 2).
Phospholipid derived saturated and unsaturated FAs tended to
decrease over 12 weeks treatment period. The levels of oleic acid(18:1, cis-9) and LA (18:1, cis-9,12), which were initially elevated,
lowered after treatment. Also signiﬁcant reduction of DHA (22:6,
cis- 4,7,10,13,16,19) and a tendency to decrease in EPA (20:5, cis-
5,8,11,14,17) and DPA (22:5, cis- 7,10,13,16,19) were noted after
sildenaﬁl use (Table 2).
Initially elevated ω6/ω3 ratio further increased from
7.3971.38 ng/mL to 7.6771.69ng/mL with sildenaﬁl therapy and,
while high levels of 4-HNE lowered signiﬁcantly after treatment,
falling even below the values observed in control group (Fig. 1).
3.5. Changes in HRV with sildenaﬁl therapy
HRV parameters in PAH improved after 12 weeks of sildenaﬁl
therapy. Time-domain indexes tended to increase but remained
lower than in control group (Table 3). Signiﬁcant increase in TP in
supine position was noted but it was still lower comparing to
control (Fig. 2). The treatment associated increase in TP in PAH
patients was predominantly on account of the VLF power with its
contribution to spectral structure 42% before vs. 56% after treat-
ment. Orthostatic test also demonstrated increase in TP on account
of the VLF power after sildenaﬁl use but both autonomic compo-
nents tended to decline further with LF power decreasing from
45% to 28% and HF power from 7% to 4% in spectral structure. At
the same time no signiﬁcant change in LF/HF ratios (3.772.2
Fig. 1. Changes in the ω6/ω3 ratios and 4-HNE in PAH patients with sildenaﬁl therapy. Note: data presented as mean7SEM; ω6/ω3 ratio was calculated as (18:2þ20:4)/
(22:5þ22:6þ20:5).
Table 3
Changes in HRV indexes in PAH patients with sildenaﬁl therapy
Parameter PAH Control
Before treatment After treatment
Supine position SDNN, ms 18.3710.1a 32.0716.5 44.379.0
RMSSD, ms 12.9711.2a 21.4723.7a 36.5711.7
pNN50,% 1.6673.62 6.9714.4 13.6712.0
LF/HF 3.772.2 3.672.6 2.774.2
Orthostasis SDNN, ms 40.9716.5 45.9717.0 45.8717.7
RMSSD, ms 19.4716.2 14.177.1 19.679.8
pNN50,% 3.9278.05 1.271.4 3.073.6
LF/HF 8.074.5 7.273.1 5.873.3
Note: data presented as mean 7 SD;
a Difference signiﬁcant comparing to control group.
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7.273.1 after in orthostasis) was noted.4. Discussion
Despite major advances in our understanding of the PAH pa-
thobiology the survival of the patients still remains unacceptably
low, which substantiates further research in this area. Currently
PAH is recognized as a multifactorial disease with metabolic re-
programming and inﬂammation and taking central stage [66]. Also
OS, which is characterized by increased production of reactiveTP VLF LF HF
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Fig. 2. Changes in frequency-domain HRV indexes in PAH patients with sildenaﬁl thera
heart rate variability; TP –total power; VLF – very low frequency; LF- low frequency; Hoxygen and nitrogen species, uncoupling of eNOS and decreased
NO bioavailability with the pathological activation of antiapoptotic
and mitogenic pathways leading to cell proliferation and ob-
literation of the pulmonary vasculature plays an important role
[62].
In this study we demonstrated signs of OS on PAH patients by
increased level of HNE in blood (Fig. 1). HNE originates from the
oxidation of the ω-6 polyunsaturated FAs, predominantly arachi-
donic acid, and is involved in the dose-dependent manner into the
regulation of various cellular functions including proliferation,
differentiation, apoptosis, cell cycle signaling, and modulation of
the inﬂammatory pathways, etc. [78,7]. The role of high levels of
HNE in the pathogenesis of the vascular disease such athero-
sclerosis, diabetes, neurodegenerative disorders is well deﬁned
and its conjugates are frequently regarded as markers of OS [7].
The contribution of HNE to the pathogenesis of PAH may be as-
sumed from its ability to reduce NO bioavailability via modulation
of its enzymatic productiony. Elevation of peroxinitrite with re-
duced tetrahydrobiopterin (BH4) levels and uncoupled eNOS was
shown in bovine aortic endothelial cells pretreated with HNE [72].
In smooth muscle cells HNE was shown to reduce NO production
through modulating gene expression and inhibiting transcrip-
tional activation of inducible NO-synthase [27]. Deleterious effects
exerted by large amount of HNE on the vasculature also include
dysfunction of the endothelial barrier through modulation of the
activities of proteins/enzymes by Michael adducts formation, im-
paired cell–cell communications, inhibition of membrane asso-
ciated enzymes and development of the pro-inﬂammatory re-
sponse [68,7]. Thus, increased levels of HNE not only conﬁrmTP VLF LF HF
0
1000
2000
3000
4000
PAH before
PAH after
Control
m
s2
py. Note: A-supine position; B-orthostatic test; data presented as mean7SD; HRV-
F – high frequency.
TV pressure gradient
Before After 
0
50
100
150
p=0.0078
m
m
 H
g
RV
Before After
2
3
4
5
6
p=0.2325
cm
6MWT
Before Atter
0
100
200
300
400
500 p=0.002
m
NTproBNP
Before After
0
2000
4000
6000
8000
p=0.0089
pg
/m
l
Fig. 3. Changes in 6MWT, echocardiographic indexes and NT-proBNP with sildenaﬁl therapy. Note: tricuspid valve (TV) pressure gradient by echocardiography improved
signiﬁcantly after 12 weeks of sildenaﬁl therapy. Also tendency to reduction of the right ventricle (RV) size was noted. Increase in the distance in 6-min walk test (6-MWT)
was associated with the reduction in the NT-proBNP level. Data presented as mean7SD, *po0.05 vs. baseline.
K. Semen et al. / Redox Biology 7 (2016) 48–57 53presence of OS in PAH patients but also contribute to the patho-
logic remodeling of the pulmonary vasculature typical of the
disease.
Early on, the role of FA and lipid metabolites in the develop-
ment of PAH have mainly addressed changes in the eicosanoid
proﬁle [2,61,69,70] and subsequently provided rationale for tar-
geting the prostacyclin (PGI2) pathway [12]. Nowadays there is
accumulating evidence on the role of FAs and their metabolism on
the arginine–NOS–NO signaling [43,56,79]. Elevated plasma levels
of free FAs were shown to modulate endothelium-dependent NO-
production and to reduce eNOS activity due to an increase in the
mitochondrial ROS production in cultured endothelial cells [26].
Oleic acid, which is abundantly found in human serum, was found
to be elevated in PAH patients in present study (Table 2). Inter-
estingly, it was shown to impair pulmonary arterial endothelium-
dependent relaxation and endothelium-independent contraction
in the canine lung injury model [34]. LA-the major ω6 acid found
in western diet which is involved in the endothelial cell activation
and potentiation of the inﬂammatory response was also increased
in PAH patients. In the study of Saraswathi et al. exploring the
mechanisms of proatherogenic action of LA in endothelial cells the
increased Ca2þ and peroxynitrite signaling was postulated as an
important pathogenetic mechanism of endothelial dysfunction
[57]. Thus, contributing potential of LA to the development of
obliterative pulmonary angiopathy, which is also characterized by
inﬂammation [30,54] may result from its proinﬂammatory action
due to the altered NO signaling.
In present study we showed some increase in DPA and DHA in
PAH patients. This can be regarded as a compensatory mechanismaimed to promote free radical production, induce antioxidant de-
fense and diminish oxidative damage through prooxidant activity.
An increase in PUFAs can also result in improved blood rheology,
activation of peroxisomal oxidation and mitochondrial energy
function. Supportive evidence of such speculation comes from the
facts that levels of HNE and LA, both of which act as the ligands of
PPARs receptors and stimulate peroxisomal function were found to
be signiﬁcantly increased in PAH (Fig. 1, Table 2). Recently, the
major shift in the metabolic substrate preference with decreased
uptake of FAs was demonstrated in the RV in rats with severe
pulmonary hypertension [25]. In the model study NOS inhibition
caused increase in the levels of arahidonic acid and DHA in the cell
membranes due to the stimulation of Δ5 desaturases activity [16].
Whether described changes of the FAs composition contribute to
the pulmonary vascular remodeling in PAH warrants further study.
More evidence which proves changes in aerobic metabolism in
PAH patients comes from study of HRV, which was markedly re-
duced (Table 3, Fig. 2). During the past decades, data has sup-
ported the concept of a modulating effect of the aerobic metabo-
lism on HRV [73]. Conditions that are known to be related to OS
and inﬂammation such as ischemic heart disease, diabetes, heart
failure were shown to be associated with the reduction of HRV
[37,38,58]. Low HRV indexes in PAH patients in present study re-
ﬂect not only alterations of the autonomic balance but also the
depth of functional metabolic dysfunction witnessed by changes in
biochemical parameters in blood. Moreover, changes in the auto-
nomic indexes derived from assessment of HRV are believed to
have independent predictive value on the long-term outcome in
heart failure patients [38]. When taking into account that one of
Fig. 4. Metabolic interactions of the L-arginine-NO pathway during sildenaﬁl
therapy. The bioavailability of NO is inﬂuenced by a complex of factors. Oxidative
stress, hypoxia, and reduced intensity of redox reactions are accompanied by in-
creased levels of free fatty acids mostly oleic, linoleic, and docosahexanoic (DHA)
with subsequent elevation of hydroxynonenal (HNE), which impairs the activity of
endothelial NO synthase (eNOS) prompting NO deﬁciency state. Moreover, elevated
levels of HNE contribute to depletion of tetrahydrobiopterin (BH4) and, thus, can
mediate uncoupling and generation of superoxide [72]. Increased HNE is also as-
sociated with accumulation of the endogenous eNOS inhibitor asymmetric di-
methylarginine [10]. Moreover, HNE was demonstrated to suppress iNOS and in-
hibit NO formation due to activation of Nrf-2 [22]. That notion is further supported
by a study demonstrating HNE directly forming adducts with transcriptional in-
hibitor Keap-1[44]. Sildenaﬁl improves NO signaling by blocking phosphodiester-
ase type 5 and increasing intracellular cGMP level leading to relaxation of smooth
muscle cells, reducing vascular remodeling and vasoconstriction. At the same time,
long term potentiation of L-arginine-NO-system by sildenaﬁl may trigger hyper-
activation of various cGMP-dependent signaling pathways, excessive prooxidant
activity and exhaustion of antioxidant potential, which results in distorted feedback
regulation. Such metabolic derangements are reﬂected by reduced heart rate
variability and worsening of its spectral structure. The efﬁcacy of long-term sil-
denaﬁl therapy may be improved by concomitant stimulation of free radical reac-
tions (FRR), maintenance of pO2 and development of mild prooxidant activity,
which can be achieved with administration of intermittent hypoxic training, use of
ﬂavonoids or various supplements used as the sources of PUFAs (ﬁsh, plant oils,
etc.).
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failure study of HRV in these patients may be of particular value.
The complex interactions of the L-arginine-NO-system are
presented in Fig. 4. Interestingly, that most of them are modulated
by the ﬂow of ROS. Overproduction of ROS results in reduction in
NO bioavailability but their certain amounts are necessary to
maintain physiological effects of the NO pathway. The level of
acetylcholine, which is known to stimulate enzymatic NO pro-
duction to the major extend is determined by the rate of alfa-ke-
toglutarate synthesis in mitochondria and, thus, their functionality
[60,78]. Therefore, optimal intensity of the redox reactions, which
precludes maintenance of O2/ROS and ATP/ADP balances in mi-
tochondria will promote functioning of the L-arginine-NO-system.
These metabolic changes can be assessed in clinical practice by
HRV, especially its autonomic components (HF, LF) in the spectral
structure.
Administration of sildenaﬁl for 3 months resulted in signiﬁcant
clinical improvement and increase in the functional capacity of the
PAH patients. It beneﬁcially inﬂuenced pulmonary hymodynamics
as suggested by echocardiographic evaluation and reduced the
level of neurohormonal activation marker NT-proBNP. These
ﬁndings are consistent with the data from the SUPER-1 clinical
trial, demonstrating sildenaﬁl to be able to increase the distance
walked in six minute and reduce mean pulmonary artery pressure
in PAH [19].By blocking PDE type 5 sildenaﬁl triggers multiple signaling
pathways involved into regulation of inﬂammation, proliferation
and apoptosis, and antioxidant defense determining the cross talk
between key transcriptional pathways NFkB/Nrf2/HIF1 [29,41,49].
This notion is supported by the recent evidence from the model
study showing upregulation of Nfr-2 after sildenaﬁl administration
[41]. Anti-inﬂammatory and antioxidant effects of sildenaﬁl were
conﬁrmed in our work by decrease in HNE level which became
even lower than in control after treatment. Decreased level of HNE
may results from improved intensity of the redox reactions and
mitochondrial function, which cause activation of the mitochon-
drial aldehyde dehydrogenase 2-a key enzyme in the detoxiﬁca-
tion of reactive aldehydes [8,24] and, thus, promote cardiopro-
tective effect of sildenaﬁl.
Reduction of the OS signs was accompanied by decrease in
unsaturated FAs, especially oleic, linoleic in phospholipids, which
may be due to inhibition of lipid peroxidation or their better uti-
lization for the maintenance of the redox balance. The level of DHA
decreased signiﬁcantly after sildenaﬁl therapy which is suggestive
about improved structural integrity of the membranes and better
functionality of the membrane bound enzymes, receptors, and ion
channels. Activity of mitochondrial KþATP and BKCa channels is
closely related to activation of NO/CO/H2S pathways [53,51,52],
which was also described with sildenaﬁl use [41]. The function of
these mitochondrial membrane-bound channels is known to be
coupled with the activity of the autonomic nervous system.
In present study administration of sildenaﬁl caused increase in
main time-domain index SDNN, which is informative about au-
tonomic control in general, and both pNN50 and RMSSD, which
reﬂect parasympathetic activity (Table 3). Signiﬁcant increase in
total spectral power after sildenaﬁl use was accompanied by in-
crease in all spectral components but predominantly VLF sugges-
tive about neurohormonal activation without major changes in LF/
HF balance. Similar tendencies were observed in orthostasis. Three
month of sildenaﬁl therapy did not restore HRV and, thus, did not
provide complete recovery of the functional metabolic disorders in
PAH. Increase in free FAs in blood after treatment may contribute
to further inhibition of eNOS [26,57] and conﬁrms incomplete
elimination of the oxidative damage, which was reﬂected by VLF
predominance and persistent sympathetic activation in spectral
structure of HRV.
It is worth noting that maintenance of NO ﬂow only on account
of the inhibition of PDE type 5 on the long run will result in
overstimulation of PKG and associated various signaling cascades,
which can lead to excessive production of NO and subsequent
formation of peroxinitrite and OS persistence [65]. On the other
hand, hypoxia and acidosis accompanying OS contribute to pro-
duction of NO from the alternative sources, namely, nitrite re-
ductase pathway involving a wide range of enzymes such as
xanthine oxidase, cytochrome oxidase etc., which may further
facilitate OS [82,35]. In our opinion, such metabolic disturbances
can be overcome through mild activation of free radical reactions,
which will promote ﬂuctuations of different ROS and oxygen
[58,74] and will help to eliminate hypoxia, signs of OS and to
normalize function of the oxygen dependent enzymes, including
NOS. Moreover, nonenzymetic production of NO in the
NO/NO2/NO3 cycle can be activated. Such approach when applied
to treatment is described as development of hormetic reaction,
which can be achieved through many prooxidant inﬂuences
[15,40,59], with the most well documented being PUFA
supplementation.
The beneﬁcial effects of the dietary omega 3 PUFAs on the
cardiovascular health are well described [33,18,80], while the
evidence of their role in PAH is rather limited. Recently, the anti-
inﬂammatory potential of PUFAs was shown to contribute to re-
verse remodeling of pulmonary vasculature in the experimental
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acylglyceride residues of DPA (22:5) lowered levels of arachidonic
acid in blood and tissue samples and reduced NF-kB, IL-8 and p38
MAPK activation, thus, causing a decrease in pulmonary artery
pressure and an improvement of the right ventricular hypertrophy
in rat [46]. In the in vitro model of human pulmonary artery
overactivity induced by endothelin-1, IL-6, TNF-α a trihy-
droxylated DHA derivative resolvin D1 was able to reverse hy-
perresponsiveness caused by proinﬂammatory treatments [30].
EPA and DHA have been reported to prevent pressure-overload
induced cardiac ﬁbrosis [9], which may be also of particular im-
portance in PAH.5. Conclusions
Nowadays, although PAH patients report clinical and hemody-
namic improvement with sildenaﬁl monotherapy the prognosis of
the disease remains serious and search for the ways to improve
treatment efﬁcacy continues. PAH is increasingly recognized as a
metabolic disease associated with OS [1,31,4], which was con-
ﬁrmed in present study. Patients with PAH were characterized by
increased HNE in blood, changes in the FAs composition with high
levels of saturated and unsaturated (oleic, LA, DHA) acids in
phospholipids as well as reduced HRV with sympathetic pre-
dominance. Sildenaﬁl improved clinical status and pulmonary
hemodynamics in PAH subjects, reduced signs of OS, modulated
FAs composition lowering oleic, LA, DPA, DHA in phospholipids,
which is suggestive about its antioxidant and anti-inﬂammatory
action. That was accompanied by some improvement of HRV in-
dexes with increase in total spectral power on account of the
neurohumoral regulatory component. At the same time, in-
complete recovery of the functional metabolic disorders in PAH
patients may be assumed from the persistent increase in free FAs
in serum, reduced HRV with sympathetic predominance in the
spectral structure after treatment comparing to control group. The
efﬁcacy of the sildenaﬁl therapy may be improved through mild
stimulation of redox reactions and formation of the hormetic re-
sponse, which facilitates not only enzymatic but also none-
nzymetic NO production. Providing options to increase the efﬁcacy
of PAH speciﬁc treatment would open new possibilities for the
patients once described to live in “the kingdom on near death”.Conﬂict of interest
The authors declare no conﬂict of interest.Acknowledgements
Several authors of this review were supported by the European
Cooperation in Science and Technology (COST Action BM1203/EU‐
ROS).References
[1] S. Aggarwal, C.M. Gross, S. Sharma, J.R. Fineman, S.M. Black, Reactive oxygen
species in pulmonary vascular remodeling, Compr. Physiol. 3 (2013)
1011–1034.
[2] A. Al-Husseini, D.S. Wijesinghe, L. Farkas, D. Kraskauskas, J.I. Drake, B. Van
Tassel, A. Abbate, C.E. Chalfant, N.F. Voelkel, Increased eicosanoid levels in the
sugen/chronic hypoxia model of severe pulmonary hypertension, Plos One 10
(2015) e0120157.
[3] P. Balakumar, G. Taneja, Fish oil and vascular endothelial protection: bench to
bedside, Free Radic. Biol. Med. 53 (2012) 271–279.
[4] J. Barnes, R.A. Dweik, Is pulmonary hypertension a metabolic disease? Am. J.Respir. Crit. Care Med. 190 (2014) 973–975.
[5] R.L. Benza, Dave P. Miller, Robyn J. Barst, David B. Badesch, Adaani E. Frost,
Michael D. McGoon, An evaluation of long-term survival from time of diag-
nosis in pulmonary arterial hypertension from the REVEAL Registry, CHEST J.
142 (2012) 448–456.
[6] M.M. Can, C. Kaymaz, N. Pochi, T. Aktimur, Impact of pulmonary arterial hy-
pertension and its therapy on indices of heart rate variability, Off. Publ. Med.
Assoc. Zenica -Doboj. Cant. Bosnia Herzeg. 10 (2013) 249–253.
[7] S.J. Chapple, X. Cheng, G.E. Mann, Effects of 4-hydroxynonenal on vascular
endothelial and smooth muscle cell redox signaling and function in health and
disease, Redox Biol. 1 (2013) 319–331.
[8] C.-H. Chen, Sun Lihan, Daria Mochly-Rosen, Mitochondrial aldehyde dehy-
drogenase and cardiac diseases, Cardiovasc. Res. 88 (2010) 51–57.
[9] J. Chen, G.C. Shearer, Q. Chen, C.L. Healy, A.J. Beyer, V.B. Nareddy, A.M. Gerdes,
W.S. Harris, T.D. O’Connell, D. Wang, Omega-3 fatty acids prevent pressure
overload–induced cardiac ﬁbrosis through activation of cyclic GMP/protein
kinase G signaling in cardiac ﬁbroblasts, Circulation 123 (2011) 584–593.
[10] L. Chen, J.-P. Zhou, D.-B. Kuang, J. Tang, Y.-J. Li, X.-P Chen, 4-HNE increases
intracellular ADMA levels in cultured HUVECs: evidence for miR-21-depen-
dent mechanisms, 2013.
[11] W.W. Christie, Preparation of ester derivatives of fatty acids for chromato-
graphic analysis, Adv. Lipid Methodol. 2 (1993) e111.
[12] B.W. Christman, Lipid mediator dysregulation in primary pulmonary hy-
pertension, CHEST J. 114 (1998) 205S–207S.
[13] J.-L. Cracowski, B. Degano, F. Chabot, J. Labarère, E. Schwedhelm, D. Monneret,
L. Iuliano, C. Schwebel, A. Chaouat, M. Reynaud-Gaubert, Independent asso-
ciation of urinary F2-isoprostanes with survival in pulmonary arterial hy-
pertension, CHEST J. 142 (2012) 869–876.
[14] A. Daiber, Daub Steffen, Bachschmid Markus, Schildknecht Stefan,
Oelze Matthias, Steven Sebastian, Schmidt Patrick, Megner Alexandra,
Wada Masayuki, Tanabe Tadashi, Protein tyrosine nitration and thiol oxidation
by peroxynitrite—Strategies to prevent these oxidative modiﬁcations, Int. J.
Mol. Sci. 14 (2013) 7542–7570.
[15] I. Dobrzyńska, B. Szachowicz-Petelska, E. Skrzydlewska, Z. Figaszewski, Effect
of sweet grass (Hierochloe odorata) on the physico-chemical properties of liver
cell membranes from rats intoxicated with ethanol, Environ. Toxicol. Phar-
macol. 35 (2013) 247–253.
[16] A.M. Dorrance, D. Graham, A. Dominiczak, R. Fraser, Inhibition of nitric oxide
synthesis increases erythrocyte membrane ﬂuidity and unsaturated fatty acid
content, Am. J. Hypertens. 13 (2000) 1194–1202.
[17] V.E. Esenabhalu, G. Schaeffer, W.F. Graier, Free fatty acid overload attenuates
Ca2þ signaling and NO production in endothelial cells, Antioxid. Redox Signal
5 (2003) 147–153.
[18] C. Ferreri, C. Chatgilialoglu, Role of fatty acid-based functional lipidomics in
the development of molecular diagnostic tools, Expert. Rev. Mol. Diagn. 12
(2012) 767–780.
[19] N. Galiè, H.A. Ghofrani, A. Torbicki, R.J. Barst, L.J. Rubin, D. Badesch, T. Fleming,
T. Parpia, G. Burgess, A. Branzi, Sildenaﬁl citrate therapy for pulmonary arterial
hypertension, N. Engl. J. Med. 353 (2005) 2148–2157.
[20] N. Galiè, M.M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J.A. Barbera,
M. Beghetti, P. Corris, S. Gaine, J.S. Gibbs, Guidelines for the diagnosis and
treatment of pulmonary hypertension, Eur. Heart J. 30 (2009) 2493–2537.
[21] N. Galiè, Marc Humbert, Gibbs Vachiery, Jean-Luc, Irene Simon, Lang,
Simonneau Torbicki, Adam, Andrew Gérald, Peacock, Anton Vonk Noordegraaf,
Maurice Beghetti, ESC/ERS Guidelines for the diagnosis and treatment of
pulmonary hypertension, Eur. Respir. J. 46 (2015) 903–975.
[22] T.N. Gatbonton-Schwager, Sushabhan Sadhukhan, Guo-Fang Zhang, John
J. Letterio, Gregory P. Tochtrop, Identiﬁcation of a negative feedback loop in
biological oxidant formation fegulated by 4-hydroxy-2-(E)-nonenal, Redox
Biol. 2 (2014) 755–763.
[23] H.A. Ghofrani, J. Pepke-Zaba, J.A. Barbera, R. Channick, A.M. Keogh, M.
A. Gomez-Sanchez, M. Kneussl, F. Grimminger, Nitric oxide pathway and
phosphodiesterase inhibitors in pulmonary arterial hypertension, J. Am. Coll.
Cardiol. 43 (2004) S68–S72.
[24] D. Gong, Hao Zhang, Shengshou Hu, Mitochondrial aldehyde dehydrogenase
2 activation and cardioprotection, J. Mol. Cell. Cardiol. 55 (2013) 58–63.
[25] B.B. Graham, R. Kumar, C. Mickael, L. Sanders, L. Gebreab, K.M. Huber,
M. Perez, P. Smith-Jones, N.J. Serkova, R.M. Tuder, Severe pulmonary hy-
pertension is associated with altered right ventricle metabolic substrate up-
take, Am. J. Physiol.-Lung Cell. Mol. Physiol. 309 (2015) L435–L440.
[26] H. Gremmels, L.M. Bevers, J.O. Fledderus, B. Braam, A.J. van Zonneveld, M.
C. Verhaar, J.A. Joles, Oleic acid increases mitochondrial reactive oxygen spe-
cies production and decreases endothelial nitric oxide synthase activity in
cultured endothelial cells, Eur. J. Pharmacol. 751 (2015) 67–72.
[27] Y. Hattori, S. Hattori, K. Kasai, 4-Hydroxynonenal prevents no production in
vascular smooth muscle cells by inhibiting nuclear factor-κB–dependent
transcriptional activation of inducible NO synthase, Arterioscler. Thromb. Vasc.
Biol. 21 (2001) 1179–1183.
[28] R. Heart, Heart rate variability standards of measurement, physiological in-
terpretation, and clinical use, Circulation 93 (1996) 1043–1065.
[29] A.R. Hemnes, A. Zaiman, H.C. Champion, PDE5A inhibition attenuates bleo-
mycin-induced pulmonary ﬁbrosis and pulmonary hypertension through in-
hibition of ROS generation and RhoA/Rho kinase activation, Am. J. Physiol.-
Lung Cell. Mol. Physiol. 294 (2008) L24–L33.
[30] R. Hiram, E. Rizcallah, C. Sirois, M. Sirois, C. Morin, S. Fortin, E. Rousseau, Re-
solvin D1 reverses reactivity and Ca2þ sensitivity induced by ET-1, TNF-α, and
K. Semen et al. / Redox Biology 7 (2016) 48–5756IL-6 in the human pulmonary artery, Am. J. Physiol.-Heart Circ. Physiol. 307
(2014) H1547–H1558.
[31] M. Humbert, H.-A. Ghofrani, The molecular targets of approved treatments for
pulmonary arterial hypertension. Thorax, 2015, thoraxjnl-2015-207170.
[32] N. Irodova, V.Z. Lankin, G.K. Konovalova, A.G. Kochetov, I.E. Chazova, Oxidative
stress in patients with primary pulmonary hypertension, Bull. Exp. Biol. Med.
133 (2002) 580–582.
[33] U.J. Jung, C. Torrejon, A.P. Tighe, R.J. Deckelbaum, n-3 Fatty acids and cardio-
vascular disease: mechanisms underlying beneﬁcial effects, Am. J. Clin. Nutr.
87 (Suppl.) (2008) 2003S–2009S.
[34] S.A. Kaﬁ, P. Scillia, C. Mélot, P.A. Gevenois, A. Pagnamenta, R. Naeije, Abnormal
pulmonary vascular tone in canine oleic acid lung injury, Crit. Care Med. 30
(2002) 1565–1569.
[35] S. Khambata Rayomand, M., Ahluwalia Amrita, “Repurposing” of xanthine
oxidoreductase as a nitrite reductase: a new paradigm for therapeutic tar-
geting in hypertension. ANTIOXIDANTS & REDOX SIGNALING, 2015.
[36] T. Kiss, K. Kovacs, A. Komocsi, A. Tornyos, P. Zalan, B. Sumegi, F. Gallyas Jr,
Novel mechanisms of sildenaﬁl in pulmonary hypertension involving cyto-
kines/chemokines, MAP kinases and Akt, Plos One 9 (2014) e104890.
[37] M.T. La Rovere, J.H. Christensen, The autonomic nervous system and cardio-
vascular disease: role of n-3 PUFAs, Vasc. Pharmacol. 71 (2015) 1–10.
[38] M.T. La Rovere, G.D. Pinna, R. Maestri, S. Barlera, M. Bernardinangeli,
M. Veniani, G.L. Nicolosi, R. Marchioli, L. Tavazzi, Autonomic markers and
cardiovascular and arrhythmic events in heart failure patients: still a place in
prognostication? Data from the GISSI‐HF trial, Eur. J. Heart Fail. 14 (2012)
1410–1419.
[39] C.-H. Lee, S.-D. Lee, H.-C. Ou, S.-C. Lai, Y.-J. Cheng, Eicosapentaenoic acid
protects against palmitic acid-induced endothelial dysfunction via activation
of the AMPK/eNOS pathway, Int. J. Mol. Sci. 15 (2014) 10334–10349.
[40] K.J. Lemmens, M.M. Sthijns, W.J. van der Vijgh, A. Bast, G.R. Haenen, The an-
tioxidant ﬂavonoid monoHER provides efﬁcient protection and induces the
innate Nrf2 mediated adaptation in endothelial cells subjected to oxidative
stress, PharmaNutrition 2 (2014) 69–74.
[41] Peyton K.J. Liu X-m, X. Wang, W. Durante, Sildenaﬁl stimulates the expression
of gaseous monoxide-generating enzymes in vascular smooth muscle cells via
distinct signaling pathways, Biochem. Pharmacol. 84 (2012) 1045–1054.
[42] M. Maggiorini, Prevention and treatment of high-altitude pulmonary edema,
Prog. Cardiovasc. Dis. 52 (2010) 500–506.
[43] N. Matesanz, G. Park, H. McAllister, W. Leahey, A. Devine, G.E. McVeigh, T.
A. Gardiner, D.M. McDonald, Docosahexaenoic acid improves the nitroso-re-
dox balance and reduces VEGF-mediated angiogenic signaling in micro-
vascular endothelial cells, Investig. Ophthalmol. Vis. Sci. 51 (2010) 6815.
[44] M. McMahon, D.J. Lamont, K.A. Beattie, J.D. Hayes, Keap1 perceives stress via
three sensors for the endogenous signaling molecules nitric oxide, zinc, and
alkenals, Proc. Natl. Acad. Sci. 107 (2010) 18838–18843.
[45] I.K. Mohan, U. Das, Effect of L-arginine-nitric oxide system on the metabolism
of essential fatty acids in chemical-induced diabetes mellitus, Pros-
taglandins Leukot. Essent. Fat. Acids 62 (2000) 35–46.
[46] C. Morin, R. Hiram, E. Rousseau, P.U. Blier, S. Fortin, Docosapentaenoic acid
monoacylglyceride reduces inﬂammation and vascular remodeling in ex-
perimental pulmonary hypertension, Am. J. Physiol.-Heart Circ. Physiol. 307
(2014) H574–H586.
[47] B. Musicki, T.J. Bivalacqua, H.C. Champion, A.L. Burnett, Sildenaﬁl promotes
eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell
mouse penis, J. Sex. Med. 11 (2014) 424–430.
[48] J. Nagendran, Stephen L. Archer, Daniel Soliman, Vikram Gurtu, Rohit Moudgil,
Alois Haromy, Chantal St Aubin, Linda Webster, Ivan M. Rebeyka, David
B. Ross, Phosphodiesterase type 5 is highly expressed in the hypertrophied
human right ventricle, and acute inhibition of phosphodiesterase type 5 im-
proves contractility, Circulation 116 (2007) 238–248.
[49] H.-S. Park, J.-W. Park, H.-J. Kim, C.W. Choi, H.-J. Lee, B.I. Kim, Y.-S. Chun, Sil-
denaﬁl alleviates bronchopulmonary dysplasia in neonatal rats by activating
the hypoxia-inducible factor signaling pathway, Am. J. Respir. Cell. Mol. Biol.
48 (2013) 105–113.
[50] A.J. Peacock, R. Naeije, L.J. Rubin (Eds.), Pulmonary Circulation: Diseases and
Their Treatment, CRC Press, Taylor & Francis, Boca Raton, FL, USA, 2011.
[51] C. Peers, C.C. Bauer, J.P. Boyle, J.L. Scragg, M.L. Dallas, Modulation of ion
channels by hydrogen sulﬁde, Antioxid. Redox Signal. 17 (2012) 95–105.
[52] N.R. Prabhakar, G.L. Semenza, Gaseous messengers in oxygen sensing, J. Mol.
Med. 90 (2012) 265–272.
[53] W.A. Pryor, K.N. Houk, C.S. Foote, J.M. Fukuto, L.J. Ignarro, G.L. Squadrito, K.J.
A. Davies, Free radical biology and medicine: it's a gas, man! Am. J. Physiol.
Regul. Integr. Comp. Physiol. 291 (2006) R491–R511.
[54] M. Rabinovitch, C. Guignabert, M. Humbert, M.R. Nicolls, Inﬂammation and
immunity in the pathogenesis of pulmonary arterial hypertension, Circ. Res.
115 (2014) 165–175.
[55] L.J. Rubin, D.B. Badesch, T.R. Fleming, N. Galiè, G. Simonneau, H.A. Ghofrani,
M. Oakes, G. Layton, M. Serdarevic-Pehar, V.V. McLaughlin, Long-term treat-
ment with sildenaﬁl citrate in pulmonary arterial hypertension: the SUPER-2
study, CHEST J. 140 (2011) 1274–1283.
[56] V. Rudolph, B.A. Freeman, Cardiovascular consequences when nitric oxide and
lipid signaling converge, Circ. Res. 105 (2009) 511–522.
[57] V. Saraswathi, G. Wu, M. Toborek, B. Hennig, Linoleic acid-induced endothelialactivation role of calcium and peroxynitrite signaling, J. Lipid Res. 45 (2004)
794–804.
[58] K. Semen, G. den Hartog, D. Kaminskyy, T. Sirota, N. Maij, Redox modulation by
Amaranth oil in human lung ﬁbroblasts, Nat. Prod. Chem. Res. 2 (2013) 2.
[59] E. Skrzydlewska, S. Sulkowski, M. Koda, B. Zalewski, L. Kanczuga-Koda,
M. Sulkowska, Lipid peroxidation and antioxidant status in colorectal cancer,
World J. Gastroenterol.: WJG 11 (2005) 403–406.
[60] A.A. Starkov, An update on the role of mitochondrial α-ketoglutarate dehy-
drogenase in oxidative stress, Mol. Cell. Neurosci. 55 (2013) 13–16.
[61] K.R. Stenmark, M.L. Morganroth, L.K. Remigio, N.F. Voelkel, R.C. Murphy, P.
M. Henson, M.M. Mathias, J.T. Reeves, Alveolar inﬂammation and arachidonate
metabolism in monocrotaline-induced pulmonary hypertension, Am. J. Phy-
siol.-Heart Circ. Physiol. 248 (1985) H859–H866.
[62] D.M. Tabima, Sheila Frizzell, Mark T. Gladwin, Reactive oxygen and nitrogen
species in pulmonary hypertension, Free Radic. Biol. Med. 52 (2012)
1970–1986.
[63] G. Taibi, Giuseppe Carruba, Vitale Miceli, Letizia Cocciadiferro,
Angela Cucchiara, Concetta M.A. Nicotra, Sildenaﬁl protects epithelial cell
through the inhibition of xanthine oxidase and the impairment of ROS pro-
duction, Free. Radic. Res. 44 (2010) 232–239.
[64] Y. Tang, G. Li, Chronic exposure to high fatty acids impedes receptor agonist-
induced nitric oxide production and increments of cytosolic Ca2þ levels in
endothelial cells, J. Mol. Endocrinol. 47 (2011) 315–326.
[65] S.R. Thomas, P.K. Witting, G.R. Drummond, Redox control of endothelial
function and dysfunction: molecular mechanisms and therapeutic opportu-
nities, Antioxid. Redox Signal. 10 (2008) 1713–1765.
[66] R.M. Tuder, S.L. Archer, P. Dorfmüller, S.C.Erzurum, C. Guignabert, E. Miche-
lakis, M. Rabinovitch, R. Schermuly, K.R.Stenmark and N.W. Morrell, Relevant
issues in the pathology andpathobiology of pulmonary hypertension, J. Am.
Coll. Cardiol. 62 (25), Suppl. D, D4-D12.
[67] R.M. Tuder, Carlyne D. Cool, Mark W. Geraci, Jun Wang, Steven H. Abman,
Laurel Wright, David Badesch, Norbert F. Voelkel, Prostacyclin synthase ex-
pression is decreased in lungs from patients with severe pulmonary hy-
pertension, Am. J. Respir. Crit. Care Med. 159 (1999) 1925–1932.
[68] P.V. Usatyuk, V. Natarajan, Hydroxyalkenals and oxidized phospholipids
modulation of endothelial cytoskeleton, focal adhesion and adherens junction
proteins in regulating endothelial barrier function, Microvasc. Res. 83 (2012)
45–55.
[69] N.F. Voelkel, S.W. Chang, T.J. McDonnell, J.Y. Westcott, J. Haynes, Role of
membrane lipids in the control of normal vascular tone, Am. Rev. Respir. Dis.
136 (1987) 214–217.
[70] B.R. Walker, N.F. Voelkel, J.T. Reeves, Pulmonary pressor response after pros-
taglandin synthesis inhibition in conscious dogs, J. Appl. Physiol. 52 (1982)
705–709.
[71] R. Wensel, C. Jilek, M. Dörr, D. Francis, H. Stadler, T. Lange, F. Blumberg,
C. Opitz, M. Pfeifer, R. Ewert, Impaired cardiac autonomic control relates to
disease severity in pulmonary hypertension, Eur. Respir. J. 34 (2009) 895–901.
[72] J. Whitsett, M.J. Picklo, J. Vasquez-Vivar, 4-Hydroxy-2-nonenal increases su-
peroxide anion radical in endothelial cells via stimulated GTP cyclohydrolase
proteasomal degradation, Arterioscler. Thromb., Vasc. Biol. 27 (2007)
2340–2347.
[73] O. Yelisyeyeva, K. Semen, G. Ostrovska, D. Kaminskyy, T. Sirota, N. Zarkovic,
D. Mazur, O. Lutsyk, K. Rybalchenko, A. Bast, The effect of Amaranth oil on
monolayers of artiﬁcial lipids and hepatocyte plasma membranes with adre-
nalin-induced stress, Food Chem. 147 (2014) 152–159.
[74] O. Yelisyeyeva, K. Semen, N. Zarkovic, D. Kaminskyy, O. Lutsyk, V. Rybalchenko,
Activation of aerobic metabolism by Amaranth oil improves heart rate varia-
bility both in athletes and patients with type 2 diabetes mellitus, Arch. Physiol.
Biochem. 118 (2012) 47–57.
[75] K. Yoshino, M. Sano, M. Fujita, I. Tomita, Formation of aliphatic aldehydes in
rat plasma and liver due to vitamin E deﬁciency, Chem. Pharm. Bull. 34 (1986)
5184–5187.
[76] C.N. Young, J.P. Fisher, K.M. Gallagher, A. Whaley‐Connell, K. Chaudhary, R.
G. Victor, G.D. Thomas, P.J. Fadel, Inhibition of nitric oxide synthase evokes
central sympatho-excitation in healthy humans, J. Physiol. 587 (2009)
4977–4986.
[77] M.V. Zakharchenko, A. Zakharchenko, N. Khunderyakova, M. Tutukina,
M. Simonova, A. Vasilieva, O. Romanova, N. Fedotcheva, E. Litvinova,
E. Maevsky, Burst of succinate dehydrogenase and α-ketoglutarate dehy-
drogenase activity in concert with the expression of genes coding for re-
spiratory chain proteins underlies short-term beneﬁcial physiological stress in
mitochondria, Int. J. Biochem. Cell. Biol. 45 (2013) 190–200.
[78] N. Zarkovic, 4-Hydroxynonenal as a bioactive marker of pathophysiological
processes, Mol. Asp. Med. 24 (2003) 281–291.
[79] S. Zhang, T. Yang, X. Xu, M. Wang, L. Zhong, Y. Yang, Z. Zhai, F. Xiao, C. Wang,
Oxidative stress and nitric oxide signaling related biomarkers in patients with
pulmonary hypertension: a case control study, BMC Pulm. Med. 15 (2015) 50.
[80] J. Zheng, T. Huang, Y. Yu, X. Hu, B. Yang, D. Li, Fish consumption and CHD
mortality: an updated meta-analysis of seventeen cohort studies, Public
Health Nutr. 15 (2012) 725–737.
[81] M. Zou, Christian Martin, Volker Ullrich, Tyrosine nitration as a mechanism of
selective inactivation of prostacyclin synthase by peroxynitrite, Biol. Chem.
378 (1997) 707–714.
K. Semen et al. / Redox Biology 7 (2016) 48–57 57[82] B.S. Zuckerbraun, P. George, M.T. Gladwin, Nitrite in pulmonary arterial hy-
pertension: therapeutic avenues in the setting of dysregulated arginine/nitric
oxide synthase signalling, Cardiovasc. Res. 89 (2011) 542–552.Dr. Khrystyna Semen, MD, PhD, associate professor, Department of Propedeutics of
Internal Medicine #2, Danylo Halystky Lviv National Medical University; Postal
address: 69, Pekarska street, 79010, Lviv, Ukraine . Tel: þ380 676702554; e-mail:
khrystyna_semen@yahoo.comProf. Olha Yelisyeyeva, PhD, DSc in Biochemistry Department of Histology, Cytol-
ogy & Embryology, Danylo Halystky Lviv National Medical University; Postal ad-
dress: 69, Pekarska street, 79010, Lviv, Ukraine. Tel: þ380 939833743; fax: þ380
322603277; e-mail: yelisol@gmail.comDr. Iwona Jarocka-Karpowicz, Department of Analytical Chemistry, Medical Uni-
versity of Bialystok; Postal address: 2D, Mickiewicza steet, 15222, Bialystok, Poland
Tel.: þ48 85 748 5486; fax: þ48 85 748 5707.Dr. Danylo Kaminskyy, PhD, associate professor, Department of Pharmaceutical,
Organic, and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical Uni-
versity, Lviv, Ukraine Postal address: 69, Pekarska street, 79010, Lviv, Ukraine. Tel:
þ380 67 738 04 71; email: dankaminskyy@gmail.comDr. Lyubomyr Solovey, MD, department chair Intensive Care Department #2, Lviv
Regional Clinical Hospital; Postal address: 7 Chernigivska str., 79010, Lviv, Ukraine.
Tel: þ380 976535493; e-mail: lyusol@ukr.netProf., dr. Elżbieta Skrzydlewska, department chair Department of Analytical
Chemistry, Medical University of Bialystok; Postal address: 2D, Mickiewicza steet,
15222, Bialystok, Poland Tel.: þ48 85 748 5486; fax: þ48 85 748 5707.; e-mail:
skrzydle@umb.edu.plProf., dr. Ostap Yavorskyi,MD, DSc, department chair Department of Propedeutics
of Internal Medicine #2, Danylo Halystky Lviv National Medical University; Postal
address: 69, Pekarska street, 79010, Lviv, Ukraine Phone: þ380 677423605 email:
yavors@mail.lviv.ua
